Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Alternext  >  Neovacs    ALNEV   FR0004032746

NEOVACS (ALNEV)
Mes dernières consult.
Most popular
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
10/10/2017 10/11/2017 10/12/2017 10/13/2017 10/16/2017 Date
0.61(c) 0.59(c) 0.58(c) 0.58(c) 0.58(c) Last
259 028 316 241 392 021 867 346 301 328 Volume
0.00% -3.28% -1.69% 0.00% 0.00% Change
More quotes
Financials (€)
Sales 2017 4,60 M
EBIT 2017 -2,97 M
Net income 2017 -
Debt 2017 -
Yield 2017 -
Sales 2018 14,0 M
EBIT 2018 -1,71 M
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 7,77x
Capi. / Sales2018 2,55x
Capitalization 35,7 M
More Financials
Company
Neovacs SA is a biotechnology company which engages in the development of active immunotherapies for treating auto-immune, inflammatory and cancerous diseases.It focuses on the development of Tumor Necrosis Factor-Kinoid for treating Crohn's disease and rheumatoid polyarthritis and... 
More about the company
Latest news on NEOVACS
09/26 NEOVACS : Publication du nombre d'actions et droits de vote au 30 juin 2017
08/04 NEOVACS : Announces the closing of a €6.0 million private placement with u.s. bi..
08/04 NEOVACS : Announces the closing of a €6.0 million private placement with u.s. bi..
07/31 NEOVACS : Successfully raises €6.0 million in private...
07/31 NEOVACS : Successfully raises €6.0 million in private placement with u.s. biotec..
07/31 NEOVACS : Successfully raises €6.0 million in private placement with u.s. biotec..
07/27 NEOVACS : regulated- information_liquidity contract juin 2017
07/26 NEOVACS : regulated-information-reglementee30062017
07/19 NEOVACS : Announces FDA Acceptance of a New IND to Expand in U.S....
07/19 NEOVACS : Announces FDA Acceptance of a New IND to Expand in U.S. IFNalpha Kinoi..
More news
Sector news : Biotechnology & Medical Research - NEC
10/05DJAppeals Court Rules Against Amgen in Patent Case -- Update
10/05DJAppeals Court Rules Against Amgen in Patent Case
09/29 Merck to stop development of hepatitis C treatments
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
09/15France's Neovacs takes on GSK and AstraZeneca in battle to treat lupus
3
09/15France's Neovacs takes on GSK and AstraZeneca in battle to treat lupus  
09/15France's Neovacs takes on GSK and AstraZeneca in battle to treat lupus  
08/04NEOVACS ANNOUNCES THE CLOSING OF A €6.0 MILLION PRIVATE PLACEMENT WITH U.S. B.. 
08/04NEOVACS ANNOUNCES THE CLOSING OF A €6.0 MILLION PRIVATE PLACEMENT WITH U.S. B.. 
More tweets
Qtime:74
Chart NEOVACS
Duration : Period :
Neovacs Technical Analysis Chart | ALNEV | FR0004032746 | 4-Traders
Technical analysis trends NEOVACS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 3,07 €
Spread / Average Target 429%
Managers
NameTitle
Miguel Sieler Chief Executive Officer & Director
Jean-Jacques Bertrand Chairman
Baptiste Pourtout Head-Finance
Géraldine Grouard-Vogel Chief Scientific Officer
Thérèse Croughs Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
NEOVACS-28.40%42
INCYTE CORPORATION14.00%24 079
QUINTILES IMS HOLDINGS INC31.30%21 478
LONZA GROUP64.29%20 495
CELLTRION, INC.--.--%18 458
ALNYLAM PHARMACEUTICALS, INC.228.53%11 283